Anebulo Pharmaceuticals (ANEB) Price & Analysis

Compare

32 Followers

ANEB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.80 - $3.42

Previous CloseN/A

Volume2.65K

Average Volume (3M)815.02K

Market Cap

$114.22M

Enterprise Value$40.13M

Total Cash (Recent Filing)$13.28M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.76

Next Earnings

Sep 17, 2025

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding41,084,732

10 Day Avg. Volume93,574

30 Day Avg. Volume815,025

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.35

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.52

Forecast

1Y Price Target

$3.00

Price Target Upside19.05% Upside

Rating ConsensusHold

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Corporate StrategyBoard approves plan to go private at a 91% premium to previous close.

Financial ResourcesAnebulo Pharmaceuticals has adequate financial resources to fund operations well into calendar year 2026.

Regulatory SupportThe company received positive reinforcement from the US FDA related to an unmet need for a treatment for children exposed to cannabis toxicity.

Bears Say

Price TargetThe analyst downgraded shares to Hold from Buy due to limited upside potential as the stock price approached the transaction price.

Stock RatingStock rating downgraded to Hold.

ValuationThe upside potential is limited as the shares approach the transaction price and exceed the 12-month price target.

Anebulo Pharmaceuticals News

Anebulo Pharmaceuticals downgraded to Hold from Buy at Maxim

Maxim analyst Michael Okunewitch downgraded Anebulo Pharmaceuticals (ANEB) to Hold from Buy. Published first on TheFly – the...

1M ago

ANEB

Anebulo Pharmaceuticals Announces Plan to Go Private

Anebulo Pharmaceuticals ( ($ANEB) ) has issued an announcement. On July 23, 2025, Anebulo Pharmaceuticals announced a plan...

1M ago

ANEB

Anebulo Pharmaceuticals price target lowered to $3 from $6 at Maxim

Maxim lowered the firm’s price target on Anebulo Pharmaceuticals (ANEB) to $3 from $6 and keeps a Buy...

4M ago

ANEB

Anebulo Pharmaceuticals Focuses on Pediatric Cannabis Toxicity Treatment

Anebulo Pharmaceuticals, Inc. ( ($ANEB) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

ANEB

Anebulo Pharmaceuticals files to sell 15.15M shares of common stock for holders

17:25 EST Anebulo Pharmaceuticals (ANEB) files to sell 15.15M shares of common stock for holders Published first on...

6M ago

ANEB

Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results

Anebulo Pharmaceuticals, Inc. ( ($ANEB) ) has released its Q2 earnings. Here is a breakdown of the information...

6M ago

ANEB

Anebulo Pharmaceuticals reports Q4 EPS (9c) vs. (11c) last year

“We are grateful to have the continued support from current investors. Having secured such meaningful financing is indicative...

7M ago

ANEB

Is ANEB a Buy, Before Earnings?

Anebulo Pharmaceuticals, Inc. (ANEB) is scheduled to report 2nd quarter earnings on 02/07/2025. Regarding Q2 estimates, Wall Street...

7M ago

ANEB

Anebulo Pharmaceuticals collaborates with FDA to advance selonabant

Anebulo Pharmaceuticals (ANEB) announced a regulatory update and the close of a capital raise. In a Phase 2...

8M ago

ANEB

Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions

Anebulo Pharmaceuticals, Inc. ( ($ANEB) ) has released its Q1 earnings. Here is a breakdown of the information...

10M ago

ANEB

ANEB Upcoming Earnings Report: What to Expect?

Anebulo Pharmaceuticals, Inc. (ANEB) is scheduled to report 1st quarter earnings on 11/08/2024. Regarding Q1 estimates, Wall Street...

10M ago

ANEB

Anebulo Pharmaceuticals Updates Corporate Presentation

Anebulo Pharmaceuticals ( ($ANEB) ) has provided an announcement. Anebulo Pharmaceuticals, Inc. has updated its Corporate Presentation, providing...

11M ago

ANEB

Anebulo Pharmaceuticals reports Q4 EPS (5c) vs. (10c) last year

“The recently awarded grant from NIDA further enables our efforts to provide a rapid and clinically impactful emergency...

11M ago

ANEB

Anebulo Pharmaceuticals, Inc. (ANEB) Q4 Earnings Cheat Sheet

Anebulo Pharmaceuticals, Inc. (ANEB) is scheduled to report 4th quarter earnings on 09/18/2024. Regarding Q4 estimates, Wall Street...

12M ago

ANEB

ANEB FAQ

What was Anebulo Pharmaceuticals’s price range in the past 12 months?

Anebulo Pharmaceuticals lowest stock price was $0.80 and its highest was $3.42 in the past 12 months.

What is Anebulo Pharmaceuticals’s market cap?

Anebulo Pharmaceuticals’s market cap is $114.22M.

When is Anebulo Pharmaceuticals’s upcoming earnings report date?

Anebulo Pharmaceuticals’s upcoming earnings report date is Sep 17, 2025 which is in 18 days.

How were Anebulo Pharmaceuticals’s earnings last quarter?

Anebulo Pharmaceuticals released its earnings results on May 13, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.01.

Is Anebulo Pharmaceuticals overvalued?

According to Wall Street analysts Anebulo Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anebulo Pharmaceuticals pay dividends?

Anebulo Pharmaceuticals does not currently pay dividends.

What is Anebulo Pharmaceuticals’s EPS estimate?

Anebulo Pharmaceuticals’s EPS estimate is -0.07.

How many shares outstanding does Anebulo Pharmaceuticals have?

Anebulo Pharmaceuticals has 41,084,732 shares outstanding.

What happened to Anebulo Pharmaceuticals’s price movement after its last earnings report?

Anebulo Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Anebulo Pharmaceuticals?

Currently, no hedge funds are holding shares in ANEB

Anebulo Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-83.37%

Trailing 12-Months

Asset Growth

133.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Anebulo Pharmaceuticals (ANEB) Earnings & Revenues

Historic Earnings Reports

ANEB Stock 12 Month Forecast

Average Price Target

$3.00

▲(19.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,2.8615384615384616,2.873076923076923,2.8846153846153846,2.896153846153846,2.9076923076923076,2.919230769230769,2.930769230769231,2.9423076923076925,2.953846153846154,2.9653846153846155,2.976923076923077,2.9884615384615385,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,2.8615384615384616,2.873076923076923,2.8846153846153846,2.896153846153846,2.9076923076923076,2.919230769230769,2.930769230769231,2.9423076923076925,2.953846153846154,2.9653846153846155,2.976923076923077,2.9884615384615385,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,2.8615384615384616,2.873076923076923,2.8846153846153846,2.896153846153846,2.9076923076923076,2.919230769230769,2.930769230769231,2.9423076923076925,2.953846153846154,2.9653846153846155,2.976923076923077,2.9884615384615385,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.2,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >